Key Takeaways Siloton secured £8.4 million from Innovate UK to accelerate development of its handheld GiraffeOCT retinal ...

The acquisition adds Encelto, the first FDA-approved treatment for adults with idiopathic MacTel type 2, to Alcon’s retina portfolio Alcon announced its acquisition of Neurotech Pharmaceuticals for ...

Significant benefits were reported in steroid-free quiescence, retinal vascular leakage, macular edema, and visual functioning No new safety signals were identified, and Priovant plans an FDA ...

LUCIA did not achieve the primary endpoint of statistical noninferiority in mean change in BCVA versus on-label aflibercept (Eylea, Regeneron) control, despite demonstrating visual improvement. Key ...

SpyGlass Pharma announced positive 4-year first-in-human (FIH) trial results for the Bimatoprost Drug Pad-IOL (BIM-IOL) System in patients with mild-to-moderate open angle glaucoma or ocular ...

Opus Genetics announced that the FDA approved its supplemental new drug application for phentolamine ophthalmic solution 0.75% (Ryzumvi) for the treatment of presbyopia. Phentolamine ophthalmic ...

Envision and VisionServe Alliance announced that their 2027 National Conference will take place May 11-14, 2027, at the Royal Sonesta Houston Galleria Hotel in Houston, Texas, bringing together ...

EyePoint announced plans to reduce its workforce by approximately 53% and end its phase 3 wet age-related macular degeneration (AMD) trials early after its investigational therapy Duravyu (vorolanib ...

RxSight appointed Taryn Conway as chief commercial officer and Frank Shields as executive vice president of sales and commercial strategy The appointments support efforts to expand customer engagement ...

Alcon announced that the FDA approved its Brytly Redness Reliever Eye Drops. With one drop, Brytly works in 1 minute to significantly reduce redness and deliver up to 12 hours of whiter, ...